On November 24, the 2024 China Health Industry Innovation Summit and the 5th "Qipu Award" Awards Ceremony were grandly held in Shanghai and the "Qipu Seed List" was announced.

The "2024 Qipu Seed List" has a total of 81 projects from four tracks: pharmaceuticals, medical devices, in vitro diagnosis, and health digital intelligence. Relying on its excellent development potential and innovative strength, Yuanvore Medicine's R & D project "Development of Engineered i-MSCs Cell Drugs for the Treatment of Osteoarthritis" stands out in the drug innovation track and is ranked among the "2024 Drug Innovation Qipu Seeds Top 10" list.

Yuanvore Medicine is a regenerative medicine company focusing on the development and application of iPSC(Induced Pluripotent Stem Cell) technology. iPSC technology is hailed as the third medical revolution after drug treatment and surgical treatment, and has shown great potential in the treatment of chronic degenerative diseases.

Ouyang Ping, chairman of Yuanvore Medicine, said that this is a high recognition of our development potential and innovative strength in the industry, and it is also a full affirmation of the clinical value of our project. Humanity's victory over disease is inseparable from scientific discovery and technological innovation. We are willing to be the vanguard of the national medical and health industry track. With scientific research innovation as the pen, and the feelings of family and country as the ink, we will constantly explore the cutting-edge areas of biomedicine, solve difficult and painful points in the industry, and contribute to the cause of human health adds bricks and tiles! At the same time, we also sincerely thank the organizers for building such an excellent platform, allowing us the opportunity to share and communicate.

  右一：元戊医学总经理&CTO 靳钧博士

Innovation is the spirit of courage to pioneer and the power to subvert the shackles of tradition. The source of medical innovation is unmet clinical needs. Every technological breakthrough opens up a new space, opens up a new incremental market, and also brings new development opportunities and economic growth points to the medical and health industry.

Osteoarthritis (OA) is a chronic joint disease with a high incidence, long course and difficult treatment, causing great pain to patients. Existing drugs are mostly used to relieve symptoms and cannot cure them. Surgery is only suitable for advanced stages and has side effects. MSCs(mesenchymal stem cells) have unique immunoregulatory functions and cartilage differentiation potential, but clinical studies have confirmed that adult-derived MSCs are prone to fibrosis after transplantation, causing cartilage hypertrophy. In order to overcome industry problems, this project is based on induced pluripotent stem cells (iPSC) to develop an innovative cell drug i-MSCs with independent intellectual property rights, aiming to repair damaged articular cartilage at the cellular level and achieve long-term treatment. Effect of osteoarthritis.

Based on the concept of "the right cells play the right function", this project innovatively applies engineering methods such as iPSC technology, gene editing technology, and iPSC induced differentiation technology to differentiate iPSC into i-MSC through mesodermal neural crest cell lines. Intraarticular injection can correct the immune microenvironment and the morphology and function of chondrocytes in patients with OA, and finally complete the regenerative repair of OA, which can provide a rich universal source of cells. Currently, the proof of concept for R&D has been completed and non-clinical research is underway.

Compared with traditional drugs, the engineered i-MSCs cell drug developed in this project represents an innovative universal cell therapy strategy. It is not only suitable for allogeneic transplantation, but is expected to widely benefit more patient groups and has strong application potential; Moreover, this cell drug only needs to be administered by simple injection, which is convenient to operate, improves the acceptability and comfort of treatment, thereby bringing a better treatment experience to patients.

Looking to the future, Yuanwu Medicine will continue to be based on technology and market-oriented, enhance its independent innovation capabilities in key core technologies, adhere to scientific exploration and clinical verification of breakthrough therapies, and bring iPSC innovative therapies to every patient in need. Contribute our wisdom and strength to promote the innovative development of the health industry in China and even the world!

About Qipu Seed List

China Healthcare Innovation Platform (CHIP) focuses on business models, management systems and technological innovation in the health industry. Through the biennial ChIP Award selection, it selects and displays innovative projects with social significance and economic value, known as the "Oscar Award of the medical and health industry."

The "Qipu Seeds" list is an award set up to pay attention to more innovative products that are in early incubation, encourage the innovative vitality of early entrepreneurial innovators, help "seeds" break ground, realize commercialization as soon as possible, and create greater value for the industry and society.

The projects of listed companies need to be original and differentiated innovation, have clear commercialization prospects, have great clinical value and academic influence, and are expected to have a greater impact on the future of the general health industry. Since its launch, this list selection has received widespread attention and positive response from health industry professionals across the country.

About Yuanvore Medicine

Shanghai Yuanvore Medicine Technology Co., Ltd. is a regenerative medicine company focusing on the development and application of iPSC(Induced Pluripotent Stem Cell) technology. It is certified as a national-level technology-based small and medium-sized enterprise. It has 30 world-leading independent intellectual property rights (including 5 invention patent authorizations, 2 PCT applications, and 12 soft authorizations), providing solutions for the application of iPSC technology in regenerative medicine to treat chronic degenerative diseases. In November 2024, Yuanwu Medicine and Shanghai City Sixth People's Hospital officially launched a metabolic disease cooperation project, which is also the first time in the world that iPSC technology has been applied to treat such diseases.

"Yuan" is the beginning, and one yuan produces three;"Wu" soil is solid and heavy, giving birth to all things. Yuanwu Medicine uses stem cells as carriers, starts from the concept of "the right cells play the right function", uses small molecules to regulate cell fate, accurately obtains target phenotypic cells while improving target cell yield, and provides for the treatment of chronic degenerative diseases. Industrialized regenerative medicine solutions, and application empowerment to aging, degradation, damage and other major health fields, creating disruptive medical value and market value.